Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Cancer Discov. 2021 Feb;11(2):233-236. doi: 10.1158/2159-8290.CD-20-1817. Epub 2020 Dec 19.

Abstract

Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 Vaccines*
  • Health Care Rationing / organization & administration*
  • Hematologic Neoplasms / complications*
  • Hematologic Neoplasms / epidemiology*
  • Humans
  • Immunity
  • Immunization Programs / organization & administration
  • Odds Ratio
  • Proportional Hazards Models
  • Public Health / methods
  • Risk
  • Risk Factors
  • Treatment Outcome
  • Vaccination

Substances

  • COVID-19 Vaccines